FY2028 EPS Estimates for Chimerix, Inc. (NASDAQ:CMRX) Decreased by Analyst

Chimerix, Inc. (NASDAQ:CMRX) – Analysts at Capital One Financial reduced their FY2028 earnings per share estimates for Chimerix in a report released on Wednesday, May 1st. Capital One Financial analyst N. Quibria now expects that the biopharmaceutical company will earn $0.07 per share for the year, down from their prior forecast of $0.13. The consensus estimate for Chimerix’s current full-year earnings is ($0.77) per share.

A number of other analysts also recently weighed in on CMRX. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a report on Friday, March 1st. Wedbush reiterated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Monday, February 12th. Finally, StockNews.com downgraded Chimerix from a “hold” rating to a “sell” rating in a report on Friday.

Chimerix Price Performance

NASDAQ CMRX opened at $0.95 on Friday. The company has a market capitalization of $85.41 million, a price-to-earnings ratio of -1.02 and a beta of 1.13. Chimerix has a twelve month low of $0.88 and a twelve month high of $1.57. The stock has a fifty day simple moving average of $1.04 and a 200 day simple moving average of $1.00.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 39.62%. During the same period last year, the company earned ($0.24) earnings per share.

Institutional Trading of Chimerix

Large investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new position in shares of Chimerix during the 3rd quarter worth about $6,240,000. Vestal Point Capital LP bought a new position in shares of Chimerix during the 4th quarter worth about $1,348,000. Bank of New York Mellon Corp boosted its position in shares of Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 387,638 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Chimerix by 17.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after purchasing an additional 72,719 shares in the last quarter. Finally, Pale Fire Capital SE boosted its position in shares of Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 112,318 shares in the last quarter. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.